Citadel Advisors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-836,737
| Closed | -$43.9M | – | 11917 |
|
|
2020
Q3 | $43.9M | Sell |
836,737
-927,248
| -53% | -$38.4M | 0.01% | 956 |
|
|
2020
Q2 | $58.7M | Buy |
1,763,985
+636,305
| +56% | +$20.3M | 0.02% | 704 |
|
|
2020
Q1 | $30.7M | Sell |
1,127,680
-917,907
| -45% | -$25.6M | 0.01% | 911 |
|
|
2019
Q4 | $40.4M | Buy |
2,045,587
+792,076
| +63% | +$12.7M | 0.02% | 908 |
|
|
2019
Q3 | $16.2M | Buy |
1,253,511
+863,896
| +222% | +$10.4M | 0.01% | 1682 |
|
|
2019
Q2 | $4.85M | Sell |
389,615
-289,494
| -43% | -$3.84M | ﹤0.01% | 3131 |
|
|
2019
Q1 | $9.87M | Buy |
679,109
+658,959
| +3,270% | +$8.42M | ﹤0.01% | 2095 |
|
|
2018
Q4 | $222K | Buy |
+20,150
| New | +$280K | ﹤0.01% | 7719 |
|
|
2018
Q2 | – | Sell |
-77,449
| Closed | -$1.66M | – | 9500 |
|
|
2018
Q1 | $1.41M | Buy |
77,449
+38,342
| +98% | +$639K | ﹤0.01% | 4278 |
|
|
2017
Q4 | $546K | Buy |
+39,107
| New | +$529K | ﹤0.01% | 5518 |
|
|
2017
Q3 | – | Sell |
-242,813
| Closed | -$4.1M | – | 8296 |
|
|
2017
Q2 | $4.1M | Buy |
+242,813
| New | +$3.7M | ﹤0.01% | 2336 |
|
|
2016
Q4 | – | Sell |
-17,582
| Closed | -$232K | – | 8108 |
|
|
2016
Q3 | $206K | Buy |
+17,582
| New | +$207K | ﹤0.01% | 6265 |
|
|
2016
Q1 | – | Sell |
-316,713
| Closed | -$3.41M | – | 8494 |
|
|
2015
Q4 | $4.7M | Sell |
316,713
-541,252
| -63% | -$9.06M | 0.01% | 1873 |
|
|
2015
Q3 | $14.1M | Buy |
857,965
+772,131
| +900% | +$15.8M | 0.01% | 1120 |
|
|
2015
Q2 | $1.96M | Sell |
85,834
-388,406
| -82% | -$7.74M | ﹤0.01% | 3080 |
|
|
2015
Q1 | $7.21M | Buy |
474,240
+104,052
| +28% | +$1.35M | 0.01% | 1695 |
|
|
2014
Q4 | $4.46M | Buy |
370,188
+288,368
| +352% | +$3.3M | ﹤0.01% | 2087 |
|
|
2014
Q3 | $928K | Sell |
81,820
-20,339
| -20% | -$232K | ﹤0.01% | 3791 |
|
|
2014
Q2 | $1.23M | Sell |
102,159
-49,256
| -33% | -$582K | ﹤0.01% | 3230 |
|
|
2014
Q1 | $1.76M | Buy |
151,415
+27,419
| +22% | +$464K | ﹤0.01% | 2787 |
|
|
2013
Q4 | $2.19M | Sell |
123,996
-69,437
| -36% | -$1.17M | ﹤0.01% | 2459 |
|
|
2013
Q3 | $2.78M | Sell |
193,433
-765,620
| -80% | -$11.7M | ﹤0.01% | 2095 |
|
|
2013
Q2 | $14.4M | Buy |
+959,053
| New | +$12.7M | 0.02% | 836 |
|
Citadel Advisors's MNTA Position: Q4 2020 in Review
Citadel Advisors sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 836,737 shares — an estimated $43.9M sold.
Citadel Advisors first reported a position in MNTA in Q2 2013 and held it in 23 quarters. The position peaked at $58.7M in Q2 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- Citadel Advisors reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- Citadel Advisors sold 836,737 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $43.9M.
- Citadel Advisors first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 23 quarters.
- Citadel Advisors's Momenta Pharmaceuticals, Inc. position peaked at $58.7M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.